262

Further preclinical and clinical trials are required to warrantee

the used of the dosage form in human beings.

The study was performed to check the release retarding

properties of the natural polymer used. It is further recommend

for future research for dose calculation for matrix transdermal

patches.

The pharmacodynamics studies to be established in diabetic

animals

A detailed pre-clinical data is yet to be established to find out

flux, lag time etc.

The study can be extrapolated to clinical trials. Since the

polymers used are of natural origin with maximum safety

7. REFERENCES

1. Insulin and Oral Anti diabetic Drug. In Satoskar RS,

Bhandarkar SD, Ainapure SS., Pharmacology and

Pharmacotherapeutics. Popular Prakashan; 2000; 874,

889,900-901.

2. Insulin and Oral Hypoglycemic Agents. In Brody, Larner,

Minneman. Human Pharmacology, Mosby Publications 1995,

541-51.

3. Oral Hypoglycemic drug. In Hardman JG, Limbira LE, Gilman

AG. Goodman and Gilman The pharmacological Basis of

Therapeutics, New York: McGraw Hill Medical Publishing

Division, 2001; 1586-87.

4. Diabetes Mellitus. In Walker R, Edwards C, Clinical Pharmacy

and Therapeutics, 2nd edition, Churchill Livingstone: 633-637.

263

5. Insulin and Oral Hypoglycemic Agents. In Barar FSK, Essentials

of Pharmacotherapeutics, S. Chand and Co. Ltd., New Delhi:

548-56.

6. Insulin, Oral hypoglycemic drug and glucagon. In: Tripathy KD,

Essentials of Medical Pharmacology, New Delhi: Jaypee Brother,

Medical Publishers (P) Ltd., 2003; 335-53.

7. Benett PH. Diabetes: Definition and Pathogenesis. In: Ronald

Kahn C, Weir GC, Joslin‘s Diabetes Mellitus. 13th ed. New Delhi:

Waverly Private Limited; 1996. 193-7.

8. Gandhi T.P. 1978, Sulphonylureas – Second Generation Drugs

Indian Drugs 6: 1978, 163-65.

9. Hypoglycemics in Elderly Patients. J. Clin. Pharm. Ther., 21(4):

243-245

10. Chien YW, Concepts and system design for rate-controlled drug

delivery in novel drug delivery systems. 2nd edn, New York:

Marcel Dekker Inc.; 1992, 50:1-42.

11. Chiao CS, Robinson JR. Sustained-release drug delivery

systems. Remington: The Science and Practice of Industrial

Pharmacy. 19th edn. Eastern Pennsylvania. Mack Publication

Company; Vol.II, 1995, 1660-75

12. Khan GM. Controlled release oral dosage forms: Some recent

advances in matrix type drug delivery systems. The Sciences;

1(5): 2001, 350-4.

13. Lee TW, Robinson R. Controlled release drug delivery systems.

Gennaro AR, Remington: The science and practice of pharmacy.

264

20th ed. Vol.1, Philadelphia: Lippincott Williams and Wilkinson;

2000.903-28.

14. Lalla JK. Introduction to oral controlled drug delivery systems.

The Eastern Pharmacist; 45: 1991, 25-28

15. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained-release

drug delivery systems using polycarbonate microspheres

capable of floating on gastric fluid. J Pharm Pharma col; 45:

1993, 21-24

16. Aulton ME. Pharmaceutics: The Science of dosage form design.

International Student edition. London: Churchill Livingstone

2002; 206-211.

17. Wab H, Robinson JR, Lee VHL. Design of oral controlled release

drug delivery systems. In: Robinson VR, Lee VHL. Controlled

Drug Delivery Fundamentals and Applications, second edition,

New York, Marcel Dekker 1987; 418-420.

18. Lapidus H, Lordi NG, Drug Release from Compressed

Hydrophilic Matrices, J. Pharm. Sci.; 57(8): 1968, 1292-1301.

19. Heller J, Use of Polymers in controlled release of active agents,

controlled drug delivery. Fundamentals and applications, J R

Robinson, V H L Lee, Marcel Dekker; New York, 1987:179-212

20. Nandita GD, Sudip KD. Controlled-release of oral dosage forms,

Formulation, Fill and Finish 2003, 10-16

21. Ratner BD, Kwok C. Characterization of delivery systems,

surface analysis and controlled release systems. In:

265

Encyclopaedia of Controlled Drug Delivery, Vol-I. Published by

John Wiley & sons. 1999; 349-362.

22. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and

Advances. 1st ed. vallabh prakashan, 2002, 156-189.

23. Landsberg L and Young JB, Physiology and Pharmacology of the

Autonomic Nervous System, in Harrison‘s Principles of Internal

Medicine (Eds. E. Braunwald, A. S. Fanci, D. L. Kasper, S. L.

Hauser, D. L. Longo and J. L. Janeson), 15th ed., Mc. Graw Hill,

New York 2001,447.

24. Rawat S, Vengurlekar S, Rakesh B, Jain S, Srikarti G.

Transdermal delivery by iontophoresis. Indian J Pharm Sci; 70:

2008, 5-10.

25. Wade Hull MS, Heat-enhanced transdermal drug delivery: A

survey paper, J Appl Res; 2: 2002, 1-9.

26. Jain S, Jain P, Jain NK. Transfersomes: a novel vesicular

carrier for enhanced transdermal delivery: development,

characterization and performance evaluation. Drug Dev Ind

Pharm.; 29: 2003, 1013-1026.

27. Wertz PW, Downing DT, In: Transdermal drug delivery;

developmental issues and research iniatives. Hadgraft J, Guy

RH, Eds. Marcel Dekker Inc.: New York. 1989, 1-22.

28. Baichwal MR. Polymer films as drug delivery systems. In:

Advances in drug delivery systems, Bombay, MSR Foundation;

1985,136-147.A

266

29. Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal

drug delivery systems, Pharmaceutical Technology 2002, 62-78

30. Chien YW, Valia KH. Development of a dynamic skin

permeation system for long term studies. Drug Dev Ind Pharm.;

10: 1984, 575-599.

31. Waiters KA. Penetration enhancers and their use in

Transderinal Therapeutic Systems, in Transdennal Drug

Delivery, Volume 35, Drugs and the Pharmaceutical Sciences

Marcel Dekker, 1989

32. Heather AE. Transdermal Drug Delivery: Penetration

Enhancement Techniques, Current Drug Delivery; 2, 2005, 23-

33

33. Stoughton R. Enhanced percutaneous penetration with 1-

dodecylazacycloheptan-2-one. Arch. Dermatol., 1982, 118: 474-

477.

34. Wertz, P.W.; Downing, D.T., In Transdermal drug delivery:

developmental issues and research iniatives, Hadgraft, J.; Guy,

R.H., Eds. Marcel Dekker Inc.: New York. 1989, 1-22.

35. Chien YW. Development of transdermal drug delivery

system. Drug Dev Ind Pharm. 13: 1987, 589-651.

36. Prausnitz MR, Mitragotri S, Langer R. Current status and future

potential of transdermal drug delivery. Nature Reviews, Drug

Discovery, 3: 2004, 115-124.

267

37. Katz M, Poulsen BJ, In Handbook of Experimental

Pharmacology, Brodie, B.B.; Gilette, J., Eds. Springer Verlag:

Berlin. 1971, 103-174.

38. Kumar, Ritesh, Philip, Anil. Modified Transdermal Technologies:

Breaking the Barriers of Drug Permeation via the Skin; Tropical

Journal of Pharmaceutical Research 6 (1): 2007, 633-644.

39. Jain N, Talegonkar S, Jain N K. New ways to enter the blood

stream: Emerging strategies in transdermal drug delivery. The

Pharma Review, 2004: 41- 59

40. Arcangelo, Virginia P. Peterson, Andrew M.;

Pharmacotherapeutics for Advanced Practice, Published by

Lippincott Williams & Wilkins, 2005, 74.

41. Tripathi KD. Essentials of Medical Pharmacology. 4th ed. New

Delhi: Medical Publishers (p) Ltd.; 1999, 142-44.

42. Kahn CR, Shechter Y. Oral hypoglycemic agents and the

pharmacology of the endocrine pancreas. In: Theodore WR, Alan

SN, Taylor P, Gilman AG, eds. Goodman and Gilman‘s The

Pharmacological Basis of Therapeutics. 8th ed. New York, NY:

McGraw-Hill; 1991, 1484.

43. Shahla Jamzad and Reza Fassihi, Development of a controlled

release low dose class II drug-Glipizide, International Journal of

Pharmaceutics, 312: 2006, 24–32.

44. Bhosale Ashok V, Hardikar Sharwaree R, Jagtap Rajesh S, Patil

Naresh B, Dhawale Sushant S, Shirsath Sanjay C, Formulation

Of Beta Cyclodextrin Complexed Controlled Release Matrix

268

Tablet Of Glipizide And Its In-Vitro Evaluation, International

Journal of PharmTech Research, 1 (3): 2009, 773-778.

45. Hosmani AH, Kasture PV, Gonjari ID, Karmarkar AB, Study of

formulation variables on properties of glipizide mucoadhesive

microspheres by factorial design, DARU, 17 (4): 2009.

46. Chowdary KPR and Rao YS. Design and In vitro and In vivo

Evaluation of Mucoadhesive Microcapsules of Glipizide for Oral

Controlled Release: A Technical Note. AAPS PharmSciTech. 4(3):

2003, 159-168, article 39.

47. Hagalavadi Nanjappa Shivakumar, Pragnesh Bharat Patel

Bapusaheb Gangadhar Desai, Purnima Ashok, Sinnathambi

Arulmozhi, Design and statistical optimization of glipizide

loaded lipospheres using response surface methodology, Acta

Pharm. 57 , 2007, 269–285.

48. Patel JK, Patel RP, Amin AF, Patel MM, Formulation and

Evaluation of Mucoadhesive Glipizide Microspheres. AAPS

Pharm SciTech.; 6(1): 2005, 49-55.

49. Bennett N, Papich MG, Hoenig M, Fettman MJ, Lappin MR.,

Evaluation of transdermal application of glipizide in a pluronic

lecithin gel to healthy cats. Am J Vet Res. 66(4): 2005, 581-588.

50. Ouyang D, Nie S, Li W, Guo H, Liu H and Pan W, Design and

evaluation of compound metformin/glipizide elementary osmotic

pump tablets. The Journal of pharmacy and pharmacology (J

Pharm Pharmacol), 57 (7), 2005, 817-20.

269

51. Radhikaa PR, Pala TK and Sivakumar T, Formulation and

Evaluation of Sustained Release Matrix Tablets of Glipizide,

Iranian Journal of Pharmaceutical Sciences, 2009: 5(4), 205-

214.

52. Thombre AG, De Noto AR and Gibbes DC. Delivery of glipizide

from asymmetric membrane capsules using encapsulated

excipients, J. Control. Rel. 60 (2-3): 1999, 333-341.

53. Jolly MS, Mayur GS and Rajashree CM. Drug release and

swelling kinetics of directly compressed glipizide sustained-

release matrices: Establishment of level A IVIVCJournal of

Controlled Release, 129 (1, 2), 2008, 49-58.

54. Kajal Ghosal, Rajan R and Nanda A. Effects of Chemical

Enhancers on the Release of Glipizide through matrix Patch,

International Journal of ChemTech Research, 1 (4): 2009, 1128-

1130.

55. Mona samalty. Determination of Glimepiride, Glibenclamide,

and related substances using monolithic column and flow

program, Journal of separation science, 13 (9): 1998, 586-597.

56. Chowdary KPR and Balatripura Sundari G, Design And

Evaluation Of Mucoadhesive Controlled Release Oral Tablets Of

Glipizide, 65 (6): 2003, 591-594.

57. Srinivas Mutalik, Nayanabhirama Udupa, Sharath Kumar, Sunil

Agarwal, Ganesh Subramanian and Averineni KR. Glipizide

matrix transdermal systems for diabetes mellitus: Preparation,

270

In vitro and preclinical studies, Life Sciences, 79 (16), 2006,

1568-1577.

58. Ammar HO, Salama HA, Ghorab M, El-Nahhas SA, Elmotasem

HA. Transdermal Delivery System for Glipizide, Current Drug

Delivery, 3 (3): 2006, 333-341.

59. Ke-Shu Yan, Ting-Xu Yan, Hong Guo, Ji-Zhong Li, Lan-Lan Wei,

Chao Wang, Shu-Fang Nie, Wei-San Pan, Evaluation of

transdermal permeability of pentoxifylline gel: In vitro skin

permeation and In vivo microdialysis using Wistar rats, Drug

Discov Ther;1(1): 2007, 78-83.

60. Lebovitz H, Melander A, Sulfonyl Ureas: basic aspects and

clinical uses, in: K. Alberti and P. Zimmet, et al. (eds.),

International Textbook of Diabetes Mellitus, 2nd edn., J. Wiley,

Chichester, 1997, 817-840.

61. Massimo MB, Glimepiride in type 2 diabetes mellitus: a review of

the worldwide therapeutic experience. Clin. Ther. 25: 2003,

799-816.

62. Ammar HO, Salama HA, Ghorab M and Mahmoud AA,

Implication of inclusion complexation of glimepiride in

cyclodextrin–polymer systems on its dissolution, stability and

therapeutic efficacy, International Journal of Pharmaceutics,

320 (1-2): 2006, 53-57.

63. Cho CW, Choi JS, Yang KH, Shin SC, Enhanced transdermal

controlled delivery of glimepiride from the ethylene-vinyl acetate

matrix, Drug Deliv. 16(6): 2009, 320-30.

271

64. Ammar HO, Salama HA, El-Nahhas SA, Elmotasem H, Design

and evaluation of chitosan films for transdermal delivery of

glimepiride, Curr Drug Deliv. 5(4): 2008, 290-8.

65. Yao Xue, Zhang Y, Xu DH, Ma Z, Chen Y, Zhao JJ, Xu SB,

Preparation and evaluation In vivo and In vitro of glimepiride

gel-matrix controlled-release patch, Acta pharmaceutica

Sinica;39(8): 2004, 640-4.

66. Nitya Anand. Natural products in India and their

applications. The Eastern Pharmacist; 28(329): 1985, 55.

67. Norman R Farnsworth. A computerized data base for

medicinal plants. The Eastern Pharmacist; 28(326): 1985,

53.

68. Naik SR. Plant derived drugs. The Eastern Pharmacist,

29(346): 1986, 35-40.

69. Handa SS. Future trends of plants as drugs. Pharmatimes,

23(4): 1991, 13-23.

70. Macleod, Edwards, Bouchier, Davidson‘s Principles and

Practice of Medicine. 15th edn. 1987, 461.

71. Ayesha Noor, Gunasekaran S, Soosai A, Manickam and

Vijayalakshmi MA, Antidiabetic activity of Aloe vera and

histology of organs in streptozotocininduced diabetic rats,

Current Science, 94 (8), 2008.

272

72. Grover JK, Yadav S, Vats V. Medicinal plants of India with

anti-diabetic potential, Journal of Ethnopharmacology, 81:

2002, 81-100.

73. Hidehiko Beppu, Yohichi Nagamura, Keisuke,

Hypoglycaemic and antidiabetic effects in mice of Aloe

arborescens Miller var. natalensis Berger, Phytotherapy

Research, 7 (7): 1993, S37–S423.

74. Subbiah Rajasekaran, Kasiappan Ravi, Karuran

Sivagnanam and Sorimuthu Subramanian, Beneficial

Effects Of Aloe Vera Leaf Gel Extract On Lipid Profile

Status In Rats With Streptozotocin Diabetes, Clinical and

Experimental Pharmacology and Physiology, 33: 2006,

232–237.

75. Al Awadi FM: Studies on the activity of individual plants of

anantidiabetic plant mixture. Acta Diabetol Lab. 24 (1),

1987, 159-164.

76. Josias Hamman, Composition and Applications of Aloe vera

Leaf Gel, Molecules, 13: 2008, 1599-1616.

77. Akira Yagi, Sahar Hegazy, Amal Kabbash and Engy Abd-El

Wahab, Possible Hypoglycemic Effect Of Aloe Vera L. High

Molecular Weight Fractions On Type 2 Diabetic Patients, Saudi

Pharmaceutical Journal, 17 (3): 2009, 210-18.

273

78. Agarry OO, Olaleye MT and Bello Michael CO, Comparative

antimicrobial activities of aloe vera gel and leaf, African Journal

of Biotechnology, 4 (12): 2005, 1413-1414.

79. Dilip George, Sham SB, Beena Antony, Comparative evaluation

of the antimicrobial efficacy of aloe vera tooth gel and two

popular commercial toothpastes: An in vitro study, General

Dentistry, 2008, 238-241.

80. Arun kumar S and Muthuselvam M, Analysis of Phytochemical

Constituents and Antimicrobial Activities of Aloe vera L. Against

Clinical Pathogens, World Journal of Agricultural Sciences 5 (5):

2008, 572-576.

81. Saeed MA, Ishtiaq Ahmad, Uzma Yaqub, Shazia Akbar, Amran

Waheed, Saleem M and Nasiruddin. Aloe Vera: A Plant Of Vital

Significance, Science Vision, 9 (1-2): 2004, 1-13.

82. Hidehiko Beppu, Kan Shimpo, Takeshi Chihara, Takaaki

Kaneko, Ikuko Tamai, Sachiyo Yamaji, Sayaka Ozaki, Hiroshi

Kuzuya and Shigeru Sonoda, Antidiabetic effects of dietary

administration of Aloe arborescens Miller components on

multiple low-dose streptozotocin-induced diabetes in mice:

Investigation on hypoglycemic action and systemic absorption

dynamics of aloe components, Journal of Ethnopharmacology,

103 (3): 2006, 468-477.

83. Ljubica Harhajia, Sanja Mijatovica, Danijela Maksimovic-

Ivanica, Dusan Popadicb, Aleksandra Isakovicc, Biljana

Todorovic-Markovicd and Vladimir, Aloe emodin inhibits the

274

cytotoxic action of tumor necrosis factor, European Journal of

Pharmacology, 568 (1-3): 2007, 248-259.

84. Chithra P, Sajithlal GB, Gowri Chandrakasan, Influence of aloe

vera on the healing of dermal wounds in diabetic rats, Journal

of Ethnopharmacology, 59: 1998, 195–201.

85. Po Lin Kuo, Ta Chen Lin, Chun Ching Lin, The antiproliferative

activity of aloe-emodin is through p53-dependent and p21-

dependent apoptotic pathway in human hepatoma cell lines,

Life Sciences, 71: 2002, 1879–1892.

86. Paolo Lissoni, Franco Rovelli, Fernando Brivio, Romano Zago,

Massimo Colciago, Giuseppina Messina, Adelio Mora and

Giorgio Porro, A Randomized Study of Chemotherapy Versus

Biochemotherapy with Chemotherapy plus Aloe arborescens in

Patients with Metastatic Cancer, in vivo 23: 2009, 171-176.

87. Acevedo-Duncan M, Russell C, Patel S, Patel R, Aloe –emodin a

noval antitumor chemotherapeutic drug, International

Immunopharmacology, 4(14): 2004, 1775-1784.

88. Louise Colea and Charles Heard, Skin permeation enhancement

potential of Aloe Vera and a proposed mechanism of action

based upon size exclusion and pull effect, International Journal

of Pharmaceutics, 333 (1-2), 2007, 10-16.

89. Chou TH, Liang CH and Sakr AM, The molecular effects of aloe-

emodin (AE)/liposome-AE on human nonmelanoma skin cancer

cells and skin permeation, Chem Res Toxicol. 22(12): 2009,

2017-28.

275

90. Elsabbagh HM. Evaluation of guar gum as a tablet additive: a

preliminary report. Pharm Ind, 39(4): 1977, 399-403.

91. Duru C. A comparative study of the disintegrating efficiency of

polysaccharides in a directly-tabletable formulation.

Pharmaceut Technol Int, 4(5): 1992, 15, 16, 20, 22 and 23.

92. Adkin DA, Kenyon CJ, Lerner EI, Landau I, Wilding IR, et al.

Use of scintigraphy to provide proof of concept for novel

polysaccharide preparations designed for colonic drug delivery.

Pharm Res; 1, 1997 103-107.

93. Wong D, Larrabee S, Clifford K, Tremblay J, Friend DN. USP

Dissolution Apparatus II for screening of guar based colonic

delivery formulations. J Controlled Release; 47: 1997, 173-179.

94. Goldstein AM, Alter EN, Seaman JK. Guar gum. Industrial

Gums, 2nd edition. New York: Academic Press, 1973: 303-321.

95. Vemuri S. Flow and consistency index dependence of

pseudoplastic guar gum solutions. Drug Dev Ind Pharm; 14:

1988, 905-914.

96. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y,

Jain SK. Cross-Linked Guar Gum Microspheres: A Viable

Approach for Improved Delivery of Anticancer Drugs for the

Treatment of Colorectal Cancer. AAPS Pharm SciTech.; 7(3):

2006, Article 74.

97. Al-Saidan SM, Krishnaiah YS, Patro SS, Satyanaryana V. In vitro

and In vivo Evaluation of Guar Gum Matrix Tablets for Oral

276

Controlled Release of Water-soluble Diltiazem Hydrochloride.

AAPS PharmSciTech.; 06(01): 2005, E14-E21

98. Udaya S. Toti and Tejraj M. Aminabhavi, Modified guar gum

matrix tablet for controlled release of diltiazem hydrochloride,

Journal of Controlled Release, 95 (3), 2004, 567-577.

99. Krishnaiah YSR, Karthikeyan RS, Gouri Sankar V,

Satyanarayana V. Three-layer guar gum matrix tablet

formulations for oral controlled delivery of highly soluble

trimetazidine dihydrochloride, Journal of Controlled Release, 81

(1): 2002, 45-56.

100. Senapati MK, Srinath A, JK Pandit, In vitro release

characteristics of matrix tablets: Study of Karaya gum and Guar

gum as release modulators, Indian Journal of Pharmaceutical

Scinces, 68 (6): 2006, 824-826.

101. Krishanaiah YSR, Development of Colon targeted oral guar

matrix tablets of albendazole for the treatment of helminthiasis

B3 adrenoceptors, an overview, Indian journal of

Pharmaceutical Scinces, 65 (4); 2003, 378-385.

102. Baweja JM, Misra AN, Studies on kinetics of drug release from

modified guar gum hydrophilic matrices, Indian journal of

Pharmaceutical Sciences: 59 (6): 1997, 316-320.

103. Deshmukh VN, Jadhav JK, Sakarkar DM, Formulation and In

vitro evaluation of theophylline anhydrous bioadhesive tablets,

Asian Journal of Pharmaceutics, 3 (1): 2007, 54-58.

277

104. Stubberud L, Arwidsson HG, Hjortsberg V, Graffner C. Water-

solid interactions. Part 3. Effect of glass transition temperature,

Tg and processing on tensile strength of compacts of lactose and

lactose/polyvinyl pyrrolidone. Pharm Dev Technol; 1(2): 1996,

195-204.

105. Iwata M, Ueda H. Dissolution properties of glibenclamide in

combinations with polyvinylpyrrolidone. Drug Dev Ind Pharm;

22: 1996, 1161-1165.

106. Wessel W, Schoog M, Winkler E. Polyvinylpyrrolidone (PVP), its

diagnostic, therapeutic and technical application and

consequences thereof. Arzneimittelforschung; 21: 1971, 1468-

1482.

107. Horn D, Ditter W. Chromatographic study of interactions

between polyvinylpyrrolidone and drugs. J Pharm Sci; 71: 1982,

1021-1026.

108. Hsiao CH, Rhodes HJ, Blake MI. Fluorescent probe study of

sulfonamide binding to povidone. J Pharm Sci; 66: 1977, 1157-

1159.

109. Jager KF, Bauer KH. Polymer blends from PVP as a means to

optimize properties of fluidized bed granulates and tablets. Acta

Pharm Technol; 30(1): 1984, 85-92.

110. Robinson BV, Sullivan FM, Borzelleca JF, Schwartz SL. PVP: A

Critical Review of the Kinetics and Toxicology of

Polyvinylpyrrolidone (Povidone). Chelsea, MI: Lewis Publishers,

1990.

278

111. Rao PR, Diwan PV, Drug diffusion from cellulose acetate-

polyvinyl pyrrolidone free films for transdermal administration,

Indian journal of Pharmaceutical Sciences, 58: 6, 1996, 246-

250.

112. Santanu Ghosh and Barik BB, Preparation and evaluation of

aceclofenac sustained release formulation and comparison of

formulated and marketed product, International Journal of

Medicine and Medical Sciences, 1 (9): 2009, 375-382.

113. Draganoiu Elena, Andheria Mahalaxmi, Adel SAKR. Evaluation

of the new polyvinylacetate/ povidone excipient for matrix

sustained release dosage forms, Pharmazeutische Industrie, 63

(6), 2001, 624-629.

114. Raghavendra Rao NG, Gandhi Sagar, Patel Tarun, Formulation

And Evaluation Of Sustained Release Matrix Tablets Of

Tramadol Hydrochloride, International Journal of Pharmacy and

Pharmaceutical Sciences, 1 (1), 2009, 60-70.

115. Sahoo J, Murthy PN, Biswal S and Manik, Formulation of

Sustained-Release Dosage Form of Verapamil Hydrochloride by

Solid Dispersion Technique Using Eudragit RLPO or Kollidon

SR, AAPS PharmSciTech. 10(1): 2009, 27–33.

116. Biswajit Mukherjeea, Sushmit a Mahapatraa, Ritu Guptab,

Balaram Patraa, Amit Tiwarib,Priyanka Arora..A comparison

between povidone-ethylcellulose and povidone-eudragit

Transdermal dexamethasone matrix patches based on In vitro

279

skin permeation. European Journal of Pharmaceutics and

Biopharmaceutics, 59, 2005, 475–483.

117. Nithiyananthan TS, Shankarananth V, Rajasekhar KK, Hareesh

G, Formulation And Evaluation Of Tamsulosin Hydrochloride As

Sustained Release Matrix Tablet, International Journal of

ChemTech Research, 1 (4): 2009, 1278-1290.

118. Satyavati GV, Raina MK, Sharma M. (Eds.) Medicinal plants of

India, Vol.1. Indian Council of Medical Research, New Delhi,

1976.

119. Subramanian PM, Misra GS, Chemical constituents of Ficus

bengalensis (Part II) Pol J Pharmacol; 30: 1978, 559-62.

120. Rimi Shukla, Kiran Anand, Prabhu KM, Suryanarayana Murthy

P, Hypoglycaemic Effect of the Water Extract of Ficus

Bengalensis in Alloxan Recovered, Mildly Diabetic and Severely

Diabetic Rabbits, Int. J. Diab. Dev. Countries, 14, 1994, 78-81

121. Rakesh Kumar Singh, Shikha Mehtaa, Dolly Jaiswala, Prashant

Kumar Raia and Geeta Wata, Antidiabetic effect of Ficus

bengalensis aerial roots in experimental animals, Journal of

Ethnopharmacology, 123 (1): 2009, 110-114.

122. Singh RK, Mehta S, Jaiswal D, Rai PK, Watal G. Antidiabetic

effect of Ficus bengalensis aerial roots in experimental animals,

J Ethnopharmacol. 123(1): 2009, 110-4.

123. Kumar RV and Augusti KT. Antidiabetic effect of a leucocyanidin

derivative isolated from the bark of Ficus bengalensis Linn. Ind

J Biochem Biophys; 26: 1989, 400-4.

280

124. Cherian S, Augusti KT. Antidiabetic effect of glycoside of

leucopelargonidin isolated from Ficus bengalensis Linn. Ind J

Exp Biol; 31: 1993, 26-9

125. Mahalingam Gayathri and Krishnan Kannabiran, antidiabetic

and ameliorative potential of Ficus bengalensis bark Extract in

streptozotocin induced diabetic rats, Indian Journal of Clinical

Biochemistry, 23 (4), 2007, 394-400

126. Shukla R, Anand K, Prabhu KM, Murthy PS.

Hypocholesterolemic effect of water extracts of the bark of

Banyan tree, Ficus bengalensis. Ind J Clin Biochem; 10: 1995,

14–18.

127. Daniel RS, Mathew BC, Devi KS, Augusti KT. Antioxidant effect

of two flavonoids from the bark of Ficus bengalensis Linn in

hyperlipidemic rats, Indian J Exp Biol. 36(9), 1998, 902-6.

128. Vinson, Joe A. Functional Food Properties of Figs. Cereal Foods

World, 44 (2):1999, 82-87.

129. Gibernau M., Buser HR, Frey JE and Hossaert MM. Volatile

compounds from extracts of figs of Ficus carica. Phytochem, 46:

1997, 241.

130. Blodgett EC and Belgin Gomec. Fig mosaic. Plant Dis. Reptr. 51:

1967, 893-896.

131. Burnett HC. Species of Ficus susceptible to the fig mosaic virus.

Proc. Florida State Hort. Soc. 73: 1960, 316-320.

132. Krishna Mohan G, Pallavi E, Ravi Kumar B, Ramesh M,

Venkatesh S. Hepatoprotective activity of Ficus carica Linn. leaf

281

extract against carbon tetrachloride-induced hepatotoxicity in

rats, DARU, 15 (3), 2007, 162-166.

133. Gond NY and Khadabadi SS, Hepatoprotective activity of Ficus

carica leaf extract on Rifampicin induced hepatic damagein rats,

indian Journal of Pharmacceutical Sciences, 2008, 364-366

134. Vinson Joe A, Zubik, Ligia, Bose, Pratima, Samman, Najwa and

Proch, John. Dried Fruits: Excellent In vitro and In vivo

Antioxidants. J. Am. Coll. Nutr. 24(1): 2005, 44-50.

135. Rahman NN, Khan M and Hasan R, Bioactive components from

Ficus glomerata, Pure & App/. Chem., 66 (10, 11), 1994, 2287-

2290.

136. Kirtikar KR and Basu BD. Indian Medicinal Plants, vol. 3, 2nd

edn. Bishen Singh Mahandra Pal Singh, Dehra Dun, 1975,

2327–2328.

137. Temsiririrkkul R, Promjid S, Sowwanee S, Tana K, Wongsatid C

and Paritas T. Herbal Taxonomy, Pharmacognosy Faculty

Pharmaceutical Science Mahidol University, 16, 1983, 45.

138. Suresh C, Jawahar L, Sabir M. Chemical examination of the

fruits of Ficus glomerata Roxb. Journal of the Indian Chemical

Society. 56 (12), 1979, 1269.

139. Satyavati GV, Raina MK, Sharma M. Medicinal Plants of India,

Indian Council of Medical Research, New Delhi, 1, 1976, 415-

421.

140. Muhammad Shoaib Akhtar and Abdel Qayum Qureshi,

Phytopharmacological Evaluation of Ficus Glomerata, Roxb.

282

Fruit for Hypoglycaemic Activity in Normal and Diabetic

Rabbits, Pakistan J. Pharm. Sci.1 (2): 1988, 87-96.

141. Rao CV, Verma AR, Vijayakumar M and Rastogi S.

Gastroprotective effect of standardized extract of Ficus

glomerata fruit on experimental gastric ulcers in rats. Journal of

Ethnopharmacology. 115 (2), 2008, 323-326.

142. Joshi Uttara and Upadhye Mohini, Evaluation of Antioxidant

Activity of Aqueous Extract Bark of Ficus glomerata, Research

J. Pharm. and Tech. 1(4): 2008, 537-538.

143. Bheemachari J, Ashok K, Joshi NH, Suresh DK and Gupta

VRM, Antidiarrhoeal Evaluation of Ficus racemosa LINN., Latex,

Acta Pharmaceutica Sciencia 49:2007, 133 -138.

144. Omray A, Omray P. Evaluation of microcrystalline cellulose as a

glidant. Indian J Pharm Sci; 48: 1986, 20-22.

145. Dittgen M, Fricke S, Gerecke H. Microcrystalline cellulose in

direct tabletting. Mfg Chem; 64(7): 1993, 17, 19, 21.

146. Landin M, Martinez-Pacheco R, Gomez-Amoza JL, Souto C,

Concheiro A, Rowe RC. Effect of country of origin on the

properties of microcrystalline cellulose. Int J Pharmaceutics; 91:

1993, 123-131.

147. Rowe RC, McKillop AG, Bray D. The effect of batch and source

variation on the crystallinity of microcrystalline cellulose. Int J

Pharmaceutics; 101: 1994, 169-172.

148. Staniforth JN, Baichwal AR, Hart JP, Heng PWS. Effect of

addition of water on the rheological and mechanical properties

283

of microcrystalline celluloses. Int J Pharmaceutics; 41: 1988,

231-236.

149. Phadke DS, Collier JL. Effect of degassing temperature on the

specific surface area and other physical properties of

magnesium stearate. Drug Dev Ind Pharm; 20 (5): 1994, 853-

858.

150. Marwaha SB, Rubinstein MH. Structure-lubricity evaluation of

magnesium stearate. Int J Pharmaceutics; 43 (3): 1988, 249-

255.

151. Desai DS, Rubitski BA, Varia, Newman AW. Physical

interactions of magnesium stearate with starch-derived

disintegrants and their effects on capsule and tablet dissolution.

Int J Pharmaceutics; 91(2-3): 1993, 217-226.

152. Butcher AE, Jones TM. Some physical characteristics of

magnesium stearate J Pharm Pharmacol; 24: 1972, 1-9.

153. Johansson ME. Granular magnesium stearate as a lubricant in

tablet formulations. Int J Pharmaceutics; 21, 1984, 307-315.

154. Manjunatha KM, Ramana MV, Satyanarayana, Design and

evaluation of diclofenac sodium controlled drug delivery

systems, Indian Journal of Pharmaceutical Sciences; 69 (3),

2007, 384-389 .

155. Mohammad Reza Siahi, Mohammad Barzegar-Jalali, Farnaz

Monajjemzadeh, Design and Evaluation of 1- and 3-Layer

Matrices of Verapamil Hydrochloride for Sustaining Its Release,

AAPS PharmSciTech; 6 (4): 2005, 626- 632, Article 77.

284

156. Bhupinder Singh, Sukhwinder Kaur Chakkal and Naveen

Ahuja, Formulation and Optimization of Controlled Release

Mucoadhesive Tablets of Atenolol Using Response Surface

Methodology. AAPS Pharm Sci Tech. 7 (1): 2006, Article 3.

157. Sourabh Jain, Yadav SK and UK Patil. Preparation and

Evaluation of Sustained Release Matrix Tablet of Furosemide

using Natural Polymers, Research J. Pharm. and Tech. 1 (4):

2008, 374-376.

158. Selim Reza M , Mohiuddin Abdul Quadir, Syed Shabbir Haider,

Comparative evaluation of plastic, hydrophobic and hydrophilic

polymers as matrices for controlled-release drug delivery,

Journal of Pharmacy and Pharmaceutical Science, 6 (2): 2003,

282-291.

159. Panna Thapa, Manish Ghimire, Alex B. Mullen and Howard N.E.

Stevens, controlled release oral delivery system containingwater

insoluble drug, kathmandu university journal of science,

engineering and technology, 1 (1): 2005, 1-10.

160. Gedela V, Murali Mohan Babu, Namballa RK, Kasina HS, Battu

JR, Namburu KK and Kolapalli VRM. In vivo Evaluation of

Modified Gum Karaya as a Carrier for Improving the Oral

Bioavailability of a Poorly Water Soluble Nimodipine, AAPS

Pharm SciTech, 2002; 3.

161. Martins OE, Olobayo OK, Sabinus O. Effect of the molecular size

of carboxy methyl cellulose and some polymers on the sustained

285

release and some polymers on the sustained release, Acta

Pharm. 56: 2006, 325–335.

162. Evelyn Ojoe, Edna Mitie Miyauchi, Tais Cobo Viviani, Vladi Olga

Consiglieri, Formulation and In vitro evaluation of theophylline

Eudragit sustainedrelease tablets, Revista Brasileira de Ciências

Farmacêuticas Brazilian Journal of Pharmaceutical Sciences, 41

(3), 2005,159-167.

163. Jonnalagadda S, Robinson DH. A Bioresorbable, Polylactide

Reservoir for Diffusional and Osmotically Controlled Drug

Delivery. AAPS Pharm SciTech, 1 (4), 2000, article 29.

164. Perioli L, Ambrogi V, Giovagnoli S, Ricci M, Blasi P, Rossi C.

Mucoadhesive Bilayered Tablets for Buccal Sustained Release of

Flurbiprofen. AAPS Pharm SciTech. 8 (3), 2007, Article 54.

165. Manjunatha KM, Ramana MV, Satyanarayana D, Design and

evaluation of diclofenac sodium controlled drug delivery

systems: 69 (3), 2007, 384-389.

166. Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB.

Controlled Release Formulation of Tramadol Hydrochloride

Using Hydrophilic and Hydrophobic Matrix System. AAPS

Pharm SciTech, 4 (3), 2003, article 31.

167. Rani M, Mishra B. Comparative In vitro and In vivo Evaluation

of Matrix, Osmotic Matrix, and Osmotic Pump Tablets for

Controlled Delivery of Diclofenac Sodium. AAPS Pharm SciTech,

5 (4), 2004, article 71.

286

168. Avachat A, Kotwal V. Design and Evaluation of Matrix-Based

Controlled Release Tablets of Diclofenac Sodium and

Chondroitin Sulphate. AAPS Pharm SciTech, 8 (4), 2007, Article

88.

169. Yeole PG, Galgatte UC, Babla IB, Nakhat PD, Design and

evaluation of Xanthan gum-based sustained release Matrix

tablets of Diclofenac sodium, 68 (2), 2006, 185-189.

170. Kondaiah A and Prakash K. Design of controlled release non-

erodible polymeric matrix tablets of theophylline using sintering

technique, Indian Journal of Pharmaceutical Sciences, 64 (3),

2002, 239-43.

171. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and In vitro,

In vivo Evaluation of Extended- release Matrix Tablet of

Zidovudine: Influence of Combination of Hydrophilic and

Hydrophobic Matrix Formers. AAPS PharmSciTech, 7(1): 2006;

Article 1.

172. Abdelkader H, Abdalla OY, Salem H. Formulation of Controlled-

Release Baclofen Matrix Tablets: Influence of Some Hydrophilic

Polymers on the Release Rate and In vitro Evaluation. AAPS

Pharm SciTech, 8 (4), 2007, Article 100.

173. Patel VM, Prajapati BG, Patel MM, Formulation, Evaluation, and

Comparison of Bilayered and Multilayered Mucoadhesive Buccal

Devices of Propranolol Hydrochloride. AAPS Pharm SciTech, 8

(1), 2007, Article 22.

287

174. Jaber Emami, Naser Tavakoli, Formulation of sustained release

lithium carbonate matrix tablets: influence of hydrophilic

materials on the release rate and In vitro -In vivo evaluation. J

Pharm Pharmaceut Sci, 7 (3), 2005, 338-344.

175. Dave BS, Amin AF, Patel MM. Gastroretentive Drug Delivery

System of Ranitidine Hydrochloride: Formulation and In vitro

Evaluation. AAPS Pharm SciTech, 5 (2), 2004, article 34.

176. Al-Taani BM, Tashtoush BM. Effect of Microenvironment pH of

Swellable and Erodable Buffered Matrices on the Release

Characteristics of Diclofenac Sodium. AAPS Pharm SciTech, 4

(3), 2003, article 43.

177. Reddy KR, Mutalik S, Reddy S. Once-Daily Sustained-Release

Matrix Tablets of Nicorandil: Formulation and In vitro

Evaluation. AAPS PharmSciTech, 4 (4), 2003, article 61.

178. Piyakulawat P, Praphairaksit N, Chantarasiri N, Muangsin N.

Preparation and Evaluation of Chitosan/Carrageenan Beads for

Controlled Release of Sodium Diclofenac. AAPS Pharm SciTech,

8 (4), 2007, Article 97.

179. Bhalekar MR, Avari J, Umalkar RA, Preparation and In vitro

evaluation of sustained release drug delivery system for

verapamil HCL, Indian Journal of Pharmaceutical Scinces, 69

(3), 2007, 418-422.

180. Arora P, Mukherjee B. Design, development, physicochemical,

and In vitro and In vivo evaluation of transdermal patches

288

containing diclofenac diethylammonium salt. J Pharm Sci. 91

(9), 2002, 2076-89.

181. Bendas ER, Tadros MI. Enhanced Transdermal Delivery of

Salbutamol Sulfate via Ethosomes. AAPS Pharm SciTech. 8 (4),

2007, Article 107.

182. Bagyalakshmi Janardhanan, Vamsikrishna RP, Manavalan R,

Ravi TK, Manna PK. Formulation Development and In vitro and

In vivo Evaluation of Membrane-Moderated Transdermal

Systems of Ampicillin Sodium in Ethanol: pH 4.7 Buffer Solvent

System. AAPS Pharm SciTech. 8 (1), 2007, Article 7.

183. Deepak G, Pundarikakshudu K., Formulation and Pharmaco-

technical Evaluation of Controlled Release Transdermal Delivery

System of Bupropion. AAPS Pharm SciTech. 4 (1), 2003, article

3.

184. Pandey S, Praveen SH, Udupa N, Formulation and evaluation of

nimesulide transdermal drug delivery systems, Indian Journal

of Pharmaceutical Sciences, 62 (5), 2000, 376-379.

185. Agrawal SS, Munjal Priya, Permeation studies of atenolol and

metoprolol tartrate from three different polymer matrices for

transdermal delivery, Indian Journal of Pharmaceutical

Sciences; 69 (4): 2007, 535-539.

186. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S.

Nanoemulsions as Vehicles for Transdermal Delivery of

Aceclofenac. AAPS Pharm SciTech, 8 (4), 2007, Article 104.

289

187. Murthy SN, Rani S, Hiremath R. Physical and Chemical

Permeation Enhancers in Transdermal Delivery of Terbutaline

Sulphate. AAPS Pharm SciTech. 2 (1), 2001, article 8.

188. Parikh DK, Ghosh TK, Feasibility of Transdermal Delivery of

Fluoxetine. AAPS Pharm SciTech. 6 (2), 2005, 144-149.

189. Sarıgullu Ozguney I, Yeşim Karasulu H, Kantarcı G, Sozer S,

Guneri T, and Ertan G. Transdermal Delivery of Diclofenac

Sodium Through Rat Skin From Various Formulations. AAPS

Pharm SciTech. 7 (4), 2006, Article 88.

190. Aqil M, Ali A, Sultana Y, Dubey K, Najmi AK, Pillai KK. In vivo

Characterization of Monolithic Matrix Type Transdermal Drug

Delivery Systems of Pinacidil Monohydrate: A Technical Note.

AAPS Pharm SciTech. 7 (1), 2006, Article 6.

191. Satturwar PM, Fulzele SV, Dorle AK, Evaluation of Polymerized

Rosin for the Formulation and Development of Transdermal

Drug Delivery System: A Technical Note. AAPS Pharm SciTech.

6 (4), 2005, 649-654.

192. Narasimha Murthy S and Shobha Rani, Physical and Chemical

Permeation Enhancers in Transdermal Delivery of Terbutaline

Sulphate, 2000, AAPS Pharm SciTech, 2 (1), 2001, Technical

Note1.

193. Malay KD and Saroj KG. Ex vivo and In vivo evaluation of

transdermal formulation of trazodone hydrochloride, Acta

Poloniae Pharmaceutica and Drug Research, 65 (4), 2008, 481-

486.

290

194. Yuveraj Singh Tanwar, Chetan Singh, Development and

evaluation of carvedilol transdermal patches, Acta Pharm. 57,

2007, 151–159.

195. Ting Li, Changshun Ren, Manli Wang, Ligang Zhao, Ximeng

Wang, Liang Fang, Optimized preparation and evaluation of

indomethacin transdermal patch, Asian Journal of

Pharmaceutical Sciences, 2 (6): 2007, 249-259.

196. Srinivas mutallik, Udupa N, Formulation development, In vitro

and In vivo evaluation of membrane controlled transdermal

systems of Glibenclamide, Journal of Pharmaceutical Sciences,

8 (1): 2005, 26-38.

197. Ekapol Limpongsa and Kraisri Umprayn, Preparation and

Evaluation of Diltiazem Hydrochloride Diffusion-Controlled

Transdermal Delivery System, AAPS PharmSciTech. 9(2): 2008,

464–470.

198. Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK.

Transdermal System of Carvedilol: Effect of Hydrophilic and

Hydrophobic Matrix on In vitro and In vivo Characteristics. AAPS

Pharm SciTech, 8 (1), 2001, Article 2S.

199. Sridevi MG, Chary DR, Krishna P and Diwan V.

Pharmacodynamic evaluation of transdermal drug delivery

system of glibenclamide in rats, Indian Journal of

Pharmacology, 32: 2000, 309-312.

291

200. The United States Pharmacopeia 27/The National Formulary

22, United States Pharmacopeial Convention, Asian Ed, 2004,

867.

201. Glicksman, M. In Gum Technology in the Food Indmry 1969,

Ch. 14, p. 509, London, Academic Press.

202. Mark L. Woolfe, a Martin F. Chaplid and Gifty Otchere, Studies

on the Mucilages Extracted from Okra Fruits (Hibiscus

esculentus L.) and Baobab Leaves (Adansonia digitata L.), J.

Sci. Fd Agric. 28, 1917, 519-529.

203. Lippincott Williams and wilkins, Remington, The science and

Practice of pharmacy, 21st edition, vol. I, 223,305, 320,756.

204. Anonymous, British Pharmacopoeia, Vol. II, 2000, A – 207 , 210

.

205. Khandelwal KR, ―Practical Pharmacognosy‖,12th edition, Nirali

prakashan, Pune, 2004,149,153,156, 157.

206. Anonymous, Quality control methods for medicinal plant

materials, World Health Organization Geneva 1998, 8.

207. Indian pharmacopoeia, 4th edition, ministry of Health and

Family welfare, Govt. of India, controller of publication, New

Delhi 1996, A- 35,37,54,89,97,109.

208. United State Pharmacopoeia, TWIN Brook Park Way, Rockville,

MD, 24, 1954, 731.

209. Lachman, L. et al. The Theory and practice of industrial

pharmacy, 4th edition, varghise publishing house, Bombay

1987, 243.

292

210. Ravin LJ and Radebaugh GW, ―Preformulation‖, Chapter 75 in

Remington‘s Pharmaceutical Sciences, 18th edition, Mack

Publishing Company, Easton, Pennsylvania, 1990.

211. Official Monographs in Indian Pharmacopoeia, Ministry of

health and welfare, Delhi, Controller of publication; 1996.

212. The United State Pharmacopoeia 24, NF 19, United state

pharmacopoeial convention, Rockville, M.D. Asian Edi., 2000

213. Banker G and Rhodes CT, Modern Pharmaceutics, Marcel

Dekker, Inc., 2000.

214. Fiese EF and Hagen TA, ―Preformulation‖, Chapter 8 in the

Theory and Practice of Industrial Pharmacy, Lea & Febiger,

Philadelphia, 1986.

215. Saleh M. Al-Saidan, Yellela S.R. Krishnaiah, Srinivas S. Patro

and Vemulapalli Satyanaryana, In vitro and In vivo Evaluation of

Guar Gum Matrix Tablets for Oral Controlled Release of Water-

soluble Diltiazem Hydrochloride, AAPS Pharm SciTech. 6 (1),

2005, Article 5

216. Rajesh KS, Venkataraju MP And Gowda DV, Effect Of

Hydrophilic Natural Gums In Formulation Of Oral-Controlled

Release Matrix Tablets Of Propranolol Hydrochloride, Pak. J.

Pharm. Sci. 22 (2): 2009, 211-219.

217. Verma PRP and Chandak AR: Development of matrix controlled

transdermal delivery systems of pentazocine: In vitro/In vivo

performance, Acta Pharm. 59, 2009, 171–186.

293

218. Aqil M, Ali A. Monilithic matrix type transdermal drug delivery

systems of 119 pinacidil monohydrate: In vitro characterization.

Eur J Pharm Biopharm, 4, 2002, 161-164.

219. Martin A, Micromeritics, Physical Pharmacy. 4th ed.

Philadelphia: Lippincott Williams & Wilkins; 2001; 423-52.

220. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice

of Industrial Pharmacy. 4th edition, Philadelphia: PA: Lea &

Febiger; 1986; 293-45.

221. Cooper J, Gunn C. Powder flow and compaction. In: Carter SJ,

eds. Tutorial Pharmacy. New Delhi, India: CBS Publishers and

Distributors; 1986: 211-233.

222. Aulton ME, Wells TI. Pharmaceutics: The Science of Dosage

Form Design. London, England: Churchill Livingstone; 1988.

223. Andreopoulos AG and Tarantili PA, J. Biomed. Appl., 2001, 16,

35.

224. Martindale: The Extra Pharmacopoeia, 31st Edn., The

Pharmaceutical Press, London, 1996, 1588.

225. The United States Pharmacopeia, XXIII. Rockville, MD: United

States Pharmacopeial Convention, Inc; 1995:801.

226. RC Rowe, PJ Sheskey, PJ Weller, Handbook of Pharmaceutical

Excipients, 4th ed. London, UK: Royal Pharmaceutical Society of

Great Britain; 2000-120.

227. Lachman LH, Lieberman A, The Theory and Practice of

Industrial Pharmacy, 4th edition, Varghese Publishing House,

Mumbai:2000;296-300

294

228. Killedar SG, Bhagwat DA, Adnaik RS, More HN and D‘souza JI.

optimization of method for determination of swelling factor of

Ispaghula husk seeds, Indian Drugs 45 (4)April 2008, 310–313.

229. Chalk JB, Patterson M, Smith MT, Eadie MJ. Correlations

between In vitro dissolution, In vivo bioavailability and

hypoglycaemic effect of oral glibenclamide. Eur J Clin

Pharmacol. 31 (2), 1986, 177–182.

230. Balant L, Fabre J, Zahnd GR. Comparison of the

pharmacokinetics of glipizide and glibenclamide in man. Eur J

Clin Pharmacol. 8 (1): 1975, 63–69.

231. Coppack SW et al, Pharmacokinetic and pharmacodynamic

studies of glibenclamide in non-insulin dependent diabetes

mellitus, Br J Clin Pharmacol; 29 (6): 1990, 673–684.

232. Ferner RE, Chaplin S. The relationship between the

pharmacokinetics and pharmacodynamic effects of oral

hypoglycaemic drugs. Clin Pharmacokinet, 12 (6): 1987, 379–

401.

233. Jing Yaoa, Ya-Qin Shib and Zhuo-Rong Lia Development of a

RP-HPLC method for screening potentially counterfeit anti-

diabetic drugs, Journal of Chromatography B, 853 (1-2): 2007,

254-259.

234. Wahlin-Boll E, Melander A. High-performance liquid

chromatographic determination of glipizide and some other

sulfonylurea drugs in serum. J Chromatogr, 64 (4), 1979, 541–

546.

295

235. Feldman JM. Glyburide: a second-generation sulfonylurea

hypoglycemic agent. History, chemistry, metabolism,

pharmacokinetics, clinical use and adverse effects.

Pharmacotherapy; 5 (2), 1985, 43–62.

236. Kobayashi K, Kimura M, Sakoguchi T, Hase A, Matsuoka A,

Kaneko S. Pharmacokinetics of gliclazide in healthy and diabetic

subjects. J Pharm Sci; 73 (12): 1984, 1684–1687.

237. Remunan C, Bretal M, Nunez A, Bila Jato JL. Accelerated

stability of sustained release tablet prepared with Gelucire. Int J

Pharm; 80: 1992, 151-159.

238. Amnuaikit C, Ikeuchi I, Ogawara K, Higaki K, Kimura T. Skin

permeation of propranolol from polymeric film containing

terpene enhancers for transdermal use, Int. J. Pharm. 289:

2005, 167–178.

239. Verma PRP, Iyer SS. Transdermal delivery of propranolol using

mixed grades of Eudragit: design and in-vitro and In vivo

evaluation. Drug Dev. Ind. Pharm.; 26: 2000, 471–476.

240. Gupta R, Mukherjee B. Development and In vitro evaluation of

Diltiazem hydrochloride transdermal patches based on

povidone-ethyl cellulose matrices. Drug Dev Ind Pharm; 29:

2003, 1-7.

241. Arora P, Mukherjee B. Design, development, physicochemical,

and In vitro and In vivo evaluation of transdermal patches

containing Diclofenac diethylammonium salt. J Pharm Sci 91:

2002, 2076-2089.

296

242. Baichwal MR, Polymer films as drug delivery systems. In:

Advances in drug delivery systems. Bombay, MSR Foundation;

1985, 136-147.

243. Costa P, Morgado R, Sousa Lobo JM. Design and evaluation of a

lorazepam transdermal delivery system, Drug Dev Ind Pharm,

23, 1997, 939-944.

244. Draize JH, Woodward GS, Calvery HO. Method for the study of

irritation and toxicity of substances applied topically to the skin

and mucus membrane. J Pharmacol Exp Ther; 82: 1994, 377-

90.

245. Singh S, Drug stability testing and shelf life determination

according to international guidelines. Pharm Tech, 1999; 23:

68-88.